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Research
To evaluate the potential of environmental
chemicals to cause harm, to estimate the risks
that chemical exposures pose to the popula-
tion, and to identify opportunities for preven-
tion and intervention, the type and extent of
adverse effects associated with exposure to a
chemical must be elucidated. To date, hazard
and risk assessments have relied largely on data
from traditional toxicologic studies, such as the
2-year, chronic toxicology and carcinogenesis
studies or the two-generation reproductive tox-
icity assay. A primary goal of these studies is to
identify whether chemical exposures cause
overt disease outcomes, such as birth defects
and neoplasia. These studies also provide data
on biological events that precede these overt
disease outcomes, often referred to as precursor
effects. Adverse effects identified in existing
hazard and risk assessments have often been
the more overt diseases or defects, rather than
events that occur earlier in the disease process.
Increasingly, toxicology assays are providing
more information on how chemicals can inter-
fere with cellular signaling or metabolism, dis-
rupt hormone homeostasis, alter gene
expression, or otherwise play a role early in dis-
ease processes. As scientific understanding of
the mechanisms through which chemical expo-
sures advance pathologic processes resulting in
disease increases, so too does the opportunity
for effective and efficient hazard identification
and risk assessment. A necessary step in incor-
porating data on early biological perturbations
is to consider how these early events relate to
the concept of “adverse effects.” The U.S.
Environmental Protection Agency (EPA)
defines an adverse effect as “a biochemical
change, functional impairment, or pathologic
lesion that affects the performance of the
whole organism, or reduces an organism’s abil-
ity to respond to an additional environmental
challenge” (U.S. EPA 2007a) and, for exam-
ple, considers such end points as alterations in
circulating levels of sex hormones to be an
adverse effect (U.S. EPA 1996). Identifying an
adverse effect forms the basis for hazard identi-
fication and for defining the critical effect for
quantitative risk assessment.
The evolution in toxicology testing from
overt disease to elucidating toxicologic path-
ways has been recognized and endorsed by the
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BACKGROUND: Assessing adverse effects from environmental chemical exposure is integral to public
health policies. Toxicology assays identifying early biological changes from chemical exposure are
increasing our ability to evaluate links between early biological disturbances and subsequent overt
downstream effects. A workshop was held to consider how the resulting data inform consideration
of an “adverse effect” in the context of hazard identification and risk assessment.
OBJECTIVES: Our objective here is to review what is known about the relationships between chemical
exposure, early biological effects (upstream events), and later overt effects (downstream events)
through three case studies (thyroid hormone disruption, antiandrogen effects, immune system disrup-
tion) and to consider how to evaluate hazard and risk when early biological effect data are available.
DISCUSSION: Each case study presents data on the toxicity pathways linking early biological pertur-
bations with downstream overt effects. Case studies also emphasize several factors that can influ-
ence risk of overt disease as a result from early biological perturbations, including background
chemical exposures, underlying individual biological processes, and disease susceptibility. Certain
effects resulting from exposure during periods of sensitivity may be irreversible. A chemical can act
through multiple modes of action, resulting in similar or different overt effects.
CONCLUSIONS: For certain classes of early perturbations, sufficient information on the disease
process is known, so hazard and quantitative risk assessment can proceed using information on
upstream biological perturbations. Upstream data will support improved approaches for consider-
ing developmental stage, background exposures, disease status, and other factors important to
assessing hazard and risk for the whole population.
KEY WORDS: adverse health effects, androgen antagonists, hazard identification, immunotoxicants,
risk assessment, science policy, thyroid hormone, toxicologic assessments. Environ Health Perspect
116:1568–1575 (2008). doi:10.1289/ehp.11516 available via http://dx.doi.org/ [Online 10 July 2008]
National Academy of Sciences and federal
agencies (Collins et al. 2008; National Research
Council 2007). These organizations note that
moving toward a focus on perturbations along
the disease pathway should result in assays that
can test more chemicals with reduced cost and
time and fewer animals, and improve the scien-
tific understanding of the relationships between
exposures and health effects.
To move toward these goals, it is neces-
sary to consider how data on early biological
changes relate to the concept of an adverse
effect and how these data might best be inte-
grated into hazard and risk assessment. To
this end, a workshop, Moving Upstream: A
Workshop on Evaluating Adverse Upstream
Endpoints for Improved Decision Making
and Risk Assessment, was held 16–17 May
2007 in Berkeley, California. 
Workshop Summary
Three case studies were presented at the work-
shop that described available data on toxico-
logic pathways connecting chemical exposures
to early upstream biological events and then to
subsequent overt effects, which are considered
“downstream”: a) thyroid hormone disruption
and related toxicities; b) antiandrogen-mediated
male reproductive effects; and c) upstream
indicators of immunosuppression. To frame
discussions in terms of implications for hazard
identification and risk assessment processes, the
case studies explored the following questions:
• What are the precursor effects or other early
biological changes linked to the case study
outcome?
• Is there sufficient evidence to associate the
upstream events with the overt downstream
effects?
• What related information would or does
enhance our understanding of the relation-
ship between the upstream event and down-
stream effects?
• Were the steps from the upstream event(s) to
the overt downstream effect(s) identified?
How does our understanding of these steps
inform the use of the upstream event as a basis
for risk assessment, particularly in situations
when we only have data on upstream events?
• How does an understanding of variability in
background biological status (e.g., susceptibil-
ity or sensitivity, genetic or otherwise) affect
our interpretation of an upstream event?
• How might each end point be influenced by
exposure to other chemicals?
• In considering an upstream biological end
point that is measured as a continuous variable
[e.g., thyroid-stimulating hormone (TSH)],
what approach should be taken in deciding
whether a certain degree of upstream change
will lead to the overt downstream outcomes
(e.g., neurodevelopmental change)? How
should changes in upstream indicators within
“normal” ranges be considered in evaluating
potential for overt downstream outcomes in
susceptible individuals and populations?
• Can the association between upstream events
and downstream effects for chemicals consid-
ered in the case study be generalized to other
chemicals that have the same upstream effects?
• What are the obstacles to the use of the
upstream event in risk assessment (hazard
identification; dose–response assessment)?
How can they be overcome?
Case Study Synopsis: 
Thyroid Hormone Disruption
and Related Toxicities
Thyroid hormone overview. The thyroid hor-
mones (TH) thyroxine (T4) and triiodothyrine
(T3) are essential to neurologic development,
skeletal growth, and normal function of the pul-
monary system, metabolism, and cardiovascular
system. This case study emphasized the effects of
thyroid disruption on neurologic development.
Hypothyroidism is a condition of persistent
deficits of TH and is diagnosed primarily by
comparing an individual’s level of TH and TSH
to population reference ranges. Untreated con-
genital (neonatal) hypothyroidism can have
severe consequences on neurologic develop-
ment. Children diagnosed with congenital
hypothyroidism are treated with T4, and even
small doses (e.g., 2 µg/kg/day) significantly
improve later cognitive performance, demon-
strating the sensitivity of the developing brain to
TH insufficiency (Oerbeck et al. 2003; Selva
et al. 2005).
Moderate maternal TH insufficiency dur-
ing pregnancy can cause lasting developmental
deficits in the child. Decrements in human
maternal T4 during the early fetal period are
associated with adverse outcomes such as
reduced IQ scores, even for small T4 deficits
that do not constitute maternal hypothyroidism
(Haddow et al. 1999; Morreale de Escobar
et al. 2000; Pop et al. 2003).
Levels of TH in the body are determined
by a complex interplay of dynamic processes,
including dietary intake of iodine (necessary
for synthesis of TH); the transport of iodine
into the thyroid; its synthesis and storage in
the thyroid gland; its release and transport
through circulation; the deiodination of T4 to
T3 in peripheral tissues; and the degradation
of TH by hepatic enzymes. TH homeostasis
is regulated through a negative feedback loop
involving the hypothalamus and pituitary.
When TH levels decline, the hypothalamus
signals the pituitary gland to release TSH,
which stimulates the thyroid to increase TH.
When levels rebound, the hypothalamus sig-
nals the pituitary to decrease TSH. Finally,
TH action is mediated through TH receptors
throughout the body.
In hazard identification and risk assess-
ment, TH levels could serve as an upstream
indicator of adverse effects on neurologic
development. Table 1 provides an overview of
Upstream adverse end points
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Table 1. Classes, mechanisms of action, and effects of thyroid-disrupting chemicals on thyroid hormone homeostasis. 
Class Mechanism Effects on thyroid hormones Chemicals
Iodine transport Inhibit uptake of iodine Decreased thyroidal synthesis of T3 and T4 Perchlorate, chlorate, bromate, nitrates, thiocyanate
Synthesis inhibitors Inhibition of thyroperoxidase Decreased thyroidal synthesis of T3 and T4 Methimazole, propylthiourea, amitrole, mancozeb, 
soy isoflavones, benzophenone 2, 
1-methyl-3-propyl-imidazole-2-thione
Transport disruption Altered binding to serum transport Unknown Hydroxylated PCBs, EMD 49209; 
proteins pentachlorophenol
Enhanced hepatic catabolism Up-regulation of Increased biliary elimination of T3 and T4 Acetochlor, phenobarbital, 3-methylcholanthrene,
glucuronylsyltransferases or PCBs, 1-methyl-3-propyl-imidazole-2-thione
sulfotransferases (via CAR/PXR 
or AhR)
Enhanced cellular transport Up-regulation of OATPs or MCT Increased biliary elimination of T3 and T4 TCPOBOP, pregnenolone-16α-carbonitrile, TCDD,
transporters via CAR/PXR or AhR rifampicin, phenobarbital, oltipraz 
Sulfotransferases Inhibition of sulfotransferases Decrease sulfation of THs Hydroxlyated PCBs, triclosan, pentachlorophenol 
Deiodinases Inhibition or upregulation Decreased peripheral synthesis of T3 FD&C Red dye no. 3, propylthiouracil, PCBs,
of deiodinases octyl-methoxycinnamate
TR agonists and antagonists Direct or indirect alterations in Altered activation of TH-dependent gene Tetrabromobisphenol A, bisphenol A, 
TR–TRE binding transcription hydroxylated PCBs
Abbreviations: AhR, aryl hydrocarbon receptor; CAR: constitutive androstane receptor; FD&C, Federal Food, Drug, and Cosmetic Act (1938); MCT, monocarboxylate transporter; OATPs,
organic anion-transporting polypeptides; PXR, pregnane X receptor; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene; TH, thyroid
hormone; TR, thyroid receptor; TRE, thyroid hormone response elements. Data from Crofton (2008). 
classes, mechanisms of action, and effects for
chemicals that disrupt TH homeostasis and
action. For example, perchlorate inhibits the
uptake of iodine, resulting in decreased synthe-
sis of TH. Polychlorinated biphenyls (PCBs)
and the pesticide acetochlor activate enzymes
in the liver that increase excretion of TH, thus
reducing circulating levels (Crofton 2008).
Factors influencing effects of thyroid-
disrupting chemicals. Susceptibility varies
markedly with life stage. The fetus, infant,
and child appear the most susceptible to neu-
rologic disruption. The permanent effects of
TH insufficiency on neurologic development
were discussed above. Infants are likely less
resistant to fluctuations in TH synthesis than
adults. The adult thyroid stores several
months’ supply of TH and the half-life of T4
in serum is 7–10 days (Greer et al. 2002;
Vulsma et al. 1989). In contrast, the newborn
thyroid stores a 1-day supply of TH and the
half life of T4 in serum is 3 days (Vulsma
et al. 1989). Therefore, effects on TH synthe-
sis have more profound consequences for
newborns than they do for adults.
Recognizing subpopulations at risk is a key
consideration in evaluating effects on TH levels
or action as adverse. Hypothyroidism is preva-
lent in the U.S. population. Between 1999 and
2002, 7.3% of the U.S. population ≥ 12 years
of age reported having thyroid disease or taking
thyroid medication. Hypothyroidism is fre-
quently undetected and therefore untreated.
This condition often persists even in those who
receive treatment. Among women receiving
thyroid hormone replacement medication,
14% had TSH and T4 measurements indicat-
ing continued hypothyroidism. Pregnancy
causes an increased demand on the thyroid
gland, and hypothyroidism is twice as com-
mon during pregnancy (Aoki et al. 2007).
The current method for assessing thyroid
health may not be predictive of adverse down-
stream effects. Thyroid health is evaluated pri-
marily by comparing an individual’s level of
TH and TSH to population reference ranges.
However, there is a substantial variability
among individuals in the level of TH that rep-
resents homeostasis, and the normal range of
fluctuations for an individual is narrower than
the normal range for a population (Figure 1).
Consequently, a TH value within the popula-
tion reference range is not necessarily normal
or healthy for the individual (Andersen et al.
2002), and TH changes within the normal
population range may therefore be associated
with adverse effects for some individuals.
Assessments considering thyroid-disrupting
chemicals (TDCs) in isolation are likely to
underestimate the potential disruption of TH
levels or action by real-world chemical mixtures.
Studies of human body burdens indicate
simultaneous human exposure to multiple
TDCs, including dioxins, PCBs, perchlorate,
brominated flame retardants, bisphenol A, and
several pesticides (Centers for Disease Control
and Prevention 2008). A mixture of 18 TDCs
(dioxins, dibenzofurans and PCBs) was tested
at doses comparable to human exposure levels
for effects on serum T4 in rats. Components of
this mixture affect T4 through two different
mechanisms of action: The dioxins, dibenzo-
furans, and dioxin-like PCBs in the mixture
activate one set of liver enzymes, and the non-
dioxin-like PCBs activate a separate set of liver
enzymes. The mixture had a dose-additive
effect on T4 at environmentally relevant doses
and a 2- to 3-fold greater than dose-additive
effect on T4 at higher doses (Crofton et al.
2005), demonstrating that exposures to chemi-
cals acting on different pathways can have
cumulative effects on an upstream marker.
Assessments considering single TDCs in isola-
tion are therefore likely to underestimate the
potential disruption of TH by real-world
exposure to chemical mixtures. It is appropri-
ate to presume cumulative effects unless there
is evidence to the contrary, and it is important
for risk assessments to consider real-life
exposure mixtures.
Challenges for assessing risks of exposure to
TDCs. Currently available mathematical mod-
els may not be able to accurately predict the
effects of mixtures containing TDCs with
multiple mechanisms of action. There are also
numerous uncertainties in extrapolating thy-
roid data from laboratory animals to estimate
effects in humans, including species differ-
ences in the expression or structure of specific
functional proteins that may affect the toxicity
of specific compounds.
TH levels influence a spectrum of health
outcomes and symptoms, in addition to neuro-
logic development. Lower T4 and higher TSH
levels are correlated with adverse effects on the
pulmonary system (Mendelson and Boggaram
1991) and cardiovascular system, including
increased blood pressure and less favorable
blood lipid profiles (Asvold et al. 2007a,
2007b). A meta-analysis of 14 epidemiologic
studies found an overall increase in risk of
coronary heart disease of > 65% in those with
subclinical hypothyroidism (elevated in TSH
with normal T4) (Rodondi et al. 2006).
Conclusions regarding thyroid data. Many
environmental chemicals are capable of dis-
rupting thyroid hormone levels, and many of
these have the effect of decreasing circulating
levels of T4. Compensatory mechanisms may
not be sufficient to counteract the potential
downstream consequences of these T4 decre-
ments. First, findings in both animals and
humans indicate that even small maternal T4
decrements within the normal population
range during pregnancy can have adverse neu-
rodevelopmental consequences, such as reduc-
tion in IQ, in the developing child. Second,
fetuses and infants do not have stored thyroid
hormone, and thus have limited capacity to
respond to thyroid hormone decrements dur-
ing critical stages of development. Third, there
is a substantial prevalence of thyroid hormone
insufficiency in the population of U.S. women,
indicating that compensatory processes are
already compromised for many individuals.
Therefore, for hazard identification pur-
poses, workshop participants agreed that
TDC exposures that would result in reduced
T4 in a population should be considered an
adverse effect. Further-upstream disruptions
that result in lowered T4 levels, such as inhi-
bition of iodine uptake, should similarly be
considered adverse when their potential con-
sequences include alteration of T4 levels.
Because additivity or synergy of TDCs with
different modes of action has been demon-
strated, and background exposure to many
TDCs is common, risk assessments should
consider simultaneous exposures to multiple
agents and account for these interactions.
Because pregnancy causes an increased
demand on the thyroid gland, pregnant women
are likely to have heightened sensitivity to thy-
roid toxicants, particularly if they have low
dietary iodine or thyroid peroxidase antibodies.
These sensitive subpopulations are likely to be
sizable; for example, 38% of 126 pregnant
women in the National Health and Nutrition
Woodruff et al.
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Figure 1. Distribution of 12 monthly measurements of total T4 in 15 healthy men (white bars) and one indi-
vidual (black bars). The distribution in one individual is about half the width of the distribution in the group.
Frequency represents number of measurements. Adapted from Andersen et al. (2002) with permission. 
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Examination Survey (NHANES), 2001–2002,
had low iodine intake (< 100 µg/L urinary
iodine) (Caldwell et al. 2005). Because thyroid
hormone levels affect cardiovascular risk fac-
tors, the potential impact of TDCs on the
health of adults in the general population also
is large. Therefore, effects on thyroid represent
a risk to the general population and not just
the developing organism.
Case Study Synopsis:
Antiandrogen-Mediated Male
Reproductive Effects
Overview of mammalian male reproductive
development. Early in fetal development,
male sexual differentiation is determined
by expression of a Y chromosome gene, the
sex-determining region Y (SRY). Appropriately
timed SRY expression results in differentiation
of Sertoli cells in the testes, initiating a cascade
of events that result in development and differ-
entiation of male reproductive structures and
regression of female structures. The interstitial
cells of the testes, Leydig cells, produce two
important hormones for male reproductive
development: the steroid sex hormone testos-
terone and the peptide hormone insulin-like-3
(INSL-3). Testosterone is necessary for differ-
entiation of the Wolffian duct into the epi-
didymis and secondary sex organs such as the
seminal vesicles. Both testosterone and INSL-3
are necessary for testicular descent in mam-
mals: Testosterone mediates transabdominal
descent of the testes (Klonisch et al. 2004),
whereas INSL-3 is necessary for gubernacular
ligament development. Contraction of the
gubernaculums causes the inguino-scrotal
descent of the testes into the scrotum (Wilson
et al. 2004). Disruption of testosterone and/or
INSL-3 production or action can result in
cryptorchidism (undescended testes), one of
the most common birth defects in humans.
Exposure to antiandrogens during fetal
life. During fetal life, there is a transient peak
in testosterone levels necessary for proper
development of male reproductive tissues.
Disruption in androgen action during this
critical time window results in a number of
abnormalities that consistently develop in lab-
oratory animals (e.g., rats and rabbits), includ-
ing retained female structures, such as nipples
in male rodents, and malformations of male
reproductive structures, such as hypospadias
(an abnormal location of the urethral opening)
and cryptorchidism.
Multiple modes of action can disrupt
androgen activity, including a decrease in
testosterone production or interference with
androgen receptor binding. Each of these
modes of action has been well described in
the literature for two different classes of
chemicals with antiandrogenic effects.
First, carboximide pesticides such as lin-
uron, vinclozolin, and procymidone are classic
antiandrogens in that they bind antagonisti-
cally to the androgen receptor (AR), interfering
with endogenous testosterone and dihydro-
testosterone binding to the AR, and thus
decreasing the expression of androgen-depen-
dent genes. In fetal rat studies, exposure to
these chemicals has been consistently associated
with retained nipples, decreased sperm counts,
decreased anogenital distance, hypospadias,
and decreased size or agenesis of the accessory
sex glands (Gray et al. 2006). The severity of
effects increases with the dose.
Second, there are certain phthalates—
industrial chemicals with widespread exposure
in the general population—that do not bind
to the AR but do interfere with androgen
activity by inhibiting testosterone synthesis.
Specifically, phthalates with four to six carbon
side-chains interfere with testosterone produc-
tion by inhibiting cholesterol uptake into the
mitochondria by steroidogenic acute regulatory
protein and by inhibiting some, but not all, of
the enzymes in the steroidogenic pathway
(Barlow et al. 2003). These phthalates have
been most consistently shown to reduce testos-
terone production in animal research to date,
though other phthalates may be important
(Gray et al. 2000; Liu et al. 2005).
Rat studies have demonstrated that a
phthalate-induced decrease in testosterone
results in a syndrome of anti-androgenic repro-
ductive abnormalities, referred to as the
“phthalate syndrome,” which is characterized
by malformations of the epididymis, vas defer-
ens, seminal vesicles, and prostate; hypospa-
dias, cryptorchidism, and testicular injury;
permanent changes (feminization) in the reten-
tion of nipples and areolae (sexually dimorphic
structures in rodents); and demasculinization
of the growth of the perineum, resulting in a
reduced anogenital distance (Mylchreest et al.
2000). As with other antiandrogenic chemicals,
the severity of effects increases with dose.
The carboximide pesticides and four to six
side-chain carbon phthalates have different
modes of action resulting in the same spectrum
of adverse outcomes in male reproductive
development. In the developing male repro-
ductive tissues, disruption of either of these
two parts of the androgen action pathway con-
verges into a final common pathway: a decrease
in androgen-dependent gene expression.
The spectrum of effects seen in phthalate
syndrome parallels a spectrum of human dis-
eases called “testicular dysgenesis syndrome”:
infertility, cryptorchidism, hypospadias, and
testicular cancer. Several epidemiologic stud-
ies have shown associations between certain
phthalate metabolites and male developmen-
tal reproductive outcomes, including short-
ened anogenital distance in male infants
prenatally exposed to phthalates (Swan et al.
2005), changes in reproductive hormone lev-
els in male infants exposed to phthalates in
breast milk (Main et al. 2006), and poor
semen quality in adult males (Hauser et al.
2006). The exposure levels in most subjects in
these studies were comparable to the general
population exposures.
Antiandrogen effects as adverse end points
in hazard identification and risk assessment.
An antiandrogenic agent, therefore—one that
reduces androgen action by any mode of
action (e.g., binding to the androgen receptor,
or via interference with androgen synthesis)—
can be predictably associated with a series of
adverse end points in animals and likely also
in humans. Several additional scientific find-
ings need also be considered when consider-
ing antiandrogen effects as upstream adverse
end points.
Specific periods during development
are uniquely susceptible to perturbations.
Experiments in rats have demonstrated that
both the dose and the timing of exposure are
important for development of phthalate syn-
drome. Gestation days 12–19 have been iden-
tified as a sensitive period in rats, during
which exposure to dibutyl phthalate induces
phthalate syndrome, with some irreversible
effects (Carruthers and Foster 2005).
Hydrolytic phthalate monoesters are the
bioactive metabolites responsible for phthalate
toxicity. Excretion of phthalate monoesters in
urine is enhanced by glucuronide conjugation.
Experiments in rats have shown the glu-
curonidation pathway is immature and ineffi-
cient during the period of susceptibility for
phthalate syndrome. This relatively low level of
glucuronidation compared to adults could ren-
der the fetus much more susceptible to the bio-
logically active phthalate metabolites during a
critical period of sexual development. Exposure
to rats during this period of gestation has
demonstrated the proportion of free phthalate
monoesters relative to glucuronidated phtha-
late monoesters in amniotic fluid is much
higher than levels in the urine of the pregnant
dam (Calafat et al. 2006).
Exposure to mixtures of AR antagonists
and androgen synthesis disruptors. More than
95% of the population from 6 to > 65 years of
age are exposed to at least five phthalates on a
regular basis (Silva et al. 2004). Recent studies
show that exposure to mixtures of chemicals
that interfere with androgen action results in
dose-additive effects. Rats exposed to a mixture
of AR antagonists, vinclozolin, procymidone,
and flutamide, all acting through the same
mode of action, at doses that would not have
caused hypospadias alone, resulted in > 50% of
the animals having hypospadias (Christiansen
et al. 2008). Rider et al. (2008) found that pre-
natal exposure to a mixture of seven phthalates
and pesticides with differing modes of action
(i.e., AR antagonist or inhibition of androgen
synthesis) produced cumulative, dose-additive
outcomes in the androgen-dependent tissues.
Upstream adverse end points
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Exposures to phthalates can result in
adverse effects from modes of action other
than disrupting testosterone synthesis. In
addition to inhibiting the production of testos-
terone, phthalates also interfere with pro-
duction of INSL-3, which is necessary for
gubernaculum development (Wilson et al.
2004) and subsequent descent of the testis into
the scrotum. Unique to phthalate exposure is
an absence of the gubernacular ligament in
males exposed in utero. Thus, phthalates can
act through two different modes of action to
cause cryptorchidism.
Conclusion regarding antiandrogen data.
The prenatal exposure of males to antiandro-
genic chemicals illustrates several important
points when considering upstream indicators
of adverse effects: First, it is necessary for expo-
sure to occur during the critical window, the
period of reproductive organ development, in
order for certain developmental effects to be
observed. Second, perturbations early in the
development of the male reproductive system
predictably result in a wide array of adverse
outcomes that are permanent and irreversible.
Third, exposures to different chemicals with
different modes of action can result in the same
outcomes due to a deficiency in androgen-
mediated gene expression. Finally, exposure to
one chemical can have multiple modes of
action with effects on the same end point. In
summary, exposures to antiandrogens can
cause adverse effects in upstream indicators,
including a reduction in fetal testosterone lev-
els or androgen receptor binding, which can
increase the risk of a constellation of down-
stream effects including cryptorchidism,
hypospadias, and, later in life, infertility.
Case Study Synopsis: Immune
Function, Immunotoxicity, and
Resistance to Infection and
Neoplasia: The Downstream
Impacts of Unintended
Immunosuppression
Immune system overview. The immune system
consists of a complex system of tissues, cells, and
soluble mediators that protects the body against
foreign substances, including infectious agents
and some types of tumor cells. Immune cells are
located throughout the body, either in discrete
organs, such as the spleen, thymus, and lymph
nodes, or in diffuse accumulations of lymphoid
and myeloid cells, as are found in association
with the skin, lungs, and gastrointestinal tract.
Destruction of infectious agents relies on both
innate and adaptive immune responses. Innate
responses are rapid, do not require clonal expan-
sion, and are stimulated by recognition of
pathogen-associated molecules by macrophages,
natural killer cells, and granulocytes. Adaptive,
or acquired antigen-specific responses, rely on
antigen recognition and subsequent events that
culminate in cell proliferation and maturation,
mediator production, and generation of long-
lived memory cells that respond rapidly on sub-
sequent exposures to the same or closely related
antigens. The acquired immune response is
mediated by two types of lymphocytes, T cells
and B cells. T cells are a source of soluble media-
tors known as cytokines that stimulate other
immune system cells, including B cells, and act
as effector cells with cytotoxic activity. B cells
mature into plasma cells, which serve to produce
immunoglobulins (Ig), or antibodies, of various
subclasses, including IgM, IgG, IgE, IgA, and
IgD. Each of these antibody subclasses serves a
unique function in the immune response.
Factors influencing immune function.
Numerous factors influence the outcome of
an encounter with an infectious agent. Innate
defenses, critical in the early phase of resis-
tance, may be overcome by large numbers of
infectious agents. The virulence of the
pathogen may also prevent effective innate
and acquired responses from eliminating
microorganisms before infection ensues. Host
attributes such as age, sex, genotype, lifestyle,
and disease status all influence immunocom-
petence, and each may influence the inci-
dence or severity of infections.
Newborns are not immunologically mature
at birth and are thus at increased risk of infec-
tion. Protective antibodies are transferred from
mother to fetus across the placenta and to the
newborn in breast milk, although passive pro-
tection decreases rapidly as these proteins are
catabolized. Average IgM and IgG antibody
levels do not reach 50% of adult levels until
7–12 months, and IgA reaches adult levels by
3–5 years. A preponderance of naive T cells
(90% vs. 50% in adults) contributes to
reduced cell-mediated immunity in the young.
Immunocompetence also declines with
advanced age; however, few studies have evalu-
ated the effects of immunotoxicants in older
laboratory animals and humans.
Studies in laboratory animals and humans
have established that extrinsic factors, including
environmental chemicals, drugs, physical
agents, and psychological factors may influence
the course of infection. Furthermore, un-
intended immunosuppression resulting from
exposure to environmental chemicals alone or
in combination with other intrinsic and extrin-
sic factors can shift the distribution of normal
immune response, resulting in an increase in
individuals classified as “immunosuppressed.”
Immunosuppressed individuals might express
alterations of immune function such as reduced
antibody production, decreased immune cell
counts, or ineffective cell signaling. Recent data
also suggest that, in addition to suppression,
developmental exposure (i.e., exposure from
birth through puberty) to certain chemicals
may shift the pattern of cytokine production,
leading to a greater incidence of allergy and
asthma (Luebke et al. 2006).
Effects on the immune system during periods
of susceptibility. In a review of select develop-
mental immunotoxicology literature, Luebke
et al. (2006) concluded that exposure to envi-
ronmental chemicals during key developmental
periods can affect immune function in labora-
tory animals. Developmental exposure sup-
presses T-cell function through adolescence in
mice and throughout adulthood in rats.
Gestational/neonatal exposure to diazepam
(DZP) and diethylstilbestrol (DES) in rodents
can cause long-lasting (up to lifetime) effects on
the immune system, including suppression of
IgM and IgG antibody responses and nonspe-
cific lymphocyte proliferation (DES) at doses
that cause only short-term immunotoxicity in
adults. Developmental exposure to DZP, lead,
or tributyltin oxide caused immunotoxicity at
lower doses in young than in mature animals,
and developmental effects were persistent.
Clinical experience indicates that adult immune
function typically recovers soon after therapeutic
immunosuppressive treatment ends. However,
the developmental data suggest that screening
chemicals exclusively in adult animals may fail
to detect persistent effects or those effects that
occur at lower doses (Luebke et al. 1999).
Immune function also declines with age, as
do the normal physiologic processes that limit
microbial invasion. Although data are limited,
this suggests that relatively small changes in
immune function resulting from chemical
exposure may have more severe consequences if
combined with normal immunosenescence.
Several epidemiologic studies have described
associations between early-life chemical expo-
sure, altered immune end points, and frequency
of infections. Increased incidence of otitis
media and respiratory infections were reported
in children exposed to PCBs (Dallaire et al.
2006; Dewailly et al. 2000; Nakanishi et al.
1985; Weisglas-Kuperus et al. 2000; Yu et al.
1998). For example, at 3 months of age, multi-
ple upstream indicators of impaired immune
function were detected in breast-fed infants
with higher PCB exposure levels, including
reduced numbers of white blood cells and lym-
phocytes, and lower serum IgA levels at 7 and
12 months of age (Dewailly et al. 2000). These
studies also reported changes in immune system
biomarkers, such as changes in blood cell
counts and T-cell subsets or decreased serum Ig
levels with increasing PCB exposures (Karmaus
et al. 2001; Weisglas-Kuperus et al. 2000).
Antibody responses to tetanus toxoid vaccine
were significantly decreased after early postnatal
PCB exposure (Heilmann et al. 2006).
Individuals with very severe forms of
immunosuppression, as occur in primary
immunodeficiency diseases and AIDS, fre-
quently develop opportunistic infections.
Xenobiotic agents are likely to cause consider-
ably more subtle immunologic effects. The
interaction among host genetics, pathogen
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virulence, and pathogen dose plays a role in
determining the frequency and severity of ill-
ness. For individuals exhibiting mild immuno-
suppression, as may be associated with
xenobiotic chemical exposure, the infectious
dose of a given pathogen may be lower than
that which would cause disease in an individual
whose immune system is functioning opti-
mally. Limited studies in populations with mild
forms of immunosuppression (e.g., under psy-
chological stress or administered immuno-
suppressive therapies) have provided qualitative
evidence that moderate changes in immune
function can also lead to an increased incidence
of infectious or neoplastic diseases (Cohen et al.
1991; Kiecolt-Glaser et al. 2002).
Conclusions regarding immunosuppression
data. In summary, exposures to environmen-
tal contaminants have the potential to affect
upstream immune indicators, including anti-
body synthesis, T-cell function, and other
measures of immunocompetence, which can
result in compromised downstream resistance
to infection. However, the impact of back-
ground levels of xenobiotics on the burden of
disease has not been clearly established. If a
positive correlation between increasing expo-
sure and disease is assumed, then even small
changes in immune function will represent an
increased risk for developing disease.
Common Themes
The case studies demonstrate that certain toxi-
city pathways are understood well enough that
screening assays to identify early biological
changes could be used for hazard identification
and risk assessment. For example, if a chemical
is found to suppress thyroid function, the asso-
ciated data could be used to assess risk for
developmental neurotoxicity, because the latter
effect can be predicted on the basis of the
mechanism of action alone. Similarly, when a
chemical is found to be antiandrogenic, the
current science would support using the data
to assess increased risk of developmental
effects. Data from whole-animal tests of the
downstream outcomes would not be required
for risk assessment of these outcomes. The
findings of this workshop support the recent
National Academy of Sciences recommenda-
tion that toxicity testing move toward the
direct assessment of upstream events along tox-
icity pathways and gradually move away from
the current whole-animal end point–based
assays (National Research Council 2007).
The workshop also explored some of the
challenges that arise when using upstream
events to assess the adverse effects of chemical
exposures during hazard identification or risk
assessment. Several common themes emerged
from the case study discussions. Some of these
themes are not unique to the use of upstream
indicators as the basis of hazard identification
and risk assessment. Rather, they underscore
issues that should be addressed in existing haz-
ard identification and risk assessment practices.
Chemical and biological background. Each
of the case studies illustrated the importance of
considering preexisting or continuous exposure
to environmental chemicals as well as preexist-
ing biological or disease susceptibilities that
contribute independently to risk of overt dis-
ease. Preexisting exposures or biological vulner-
abilities can increase the baseline risk of the
population or enhance already initiated disease
processes (Figure 2). Consequently, slight per-
turbations in upstream biological indicators are
more likely to increase risk of subsequent
downstream events given an already more acti-
vated state among segments of the population.
Chemical background and exposure to
mixtures. NHANES data indicate that the
entire U.S. population has measurable levels of
multiple environmental contaminants in their
bodies (Centers for Disease Control and
Prevention 2008). Other studies of exposure
pathways show the population is in constant
contact with xenobiotics in air, food, water,
and consumer products (Environmental
Working Group 2005, 2007; National Library
of Medicine 2008; U.S. EPA 2007b; U.S.
Food and Drug Administration 2007). U.S.
EPA guidelines for mixtures risk assessment
recommend default assumptions of dose addi-
tivity for mixtures of chemicals with similar
toxicologic activity and response additivity for
mixtures of chemicals that act independently
(U.S. EPA 2000a). The case studies showed
that these preexisting and concurrent exposures
can increase the effect a given chemical expo-
sure has on disease risk, consistent with the
dose-additivity default. For example, separate
studies of antiandrogenic chemicals and thy-
roid-disrupting chemicals found that mixtures
of chemicals acting on common systems via
different modes of action had dose-additive
effects. Although a less-than-additive response
[referred to in the U.S. EPA mixtures guide-
lines as “antagonism” (U.S. EPA 2000a)], or a
greater than additive response (“synergism”)
are possibilities, the case studies support appli-
cation of dose additivity as a default, as recom-
mended in the guidelines. Considering the
influence of multiple chemical exposures on
upstream events can facilitate a more realistic
characterization of the risks of downstream
effects when assessing a single chemical that is
an additional increment to the background
exposure mixture.
Biological background. Background
health status, as influenced by age, preexisting
disease, genetics, and other factors, can influ-
ence the effect of chemical exposure on
upstream and downstream adverse end points.
For example, the implications of a chemical’s
interference with iodine uptake into the thy-
roid are substantially greater for an infant than
for an adult because of differences in thyroid
hormone storage and circulating half life.
Likewise, the implications are greater for the
38% of pregnant women in the United States
who are deficient in iodine (Aoki et al. 2007)
and who simultaneously have greater thyroid
hormone needs to support the neurologic
development of a fetus. Individuals with pre-
existing immune suppression, such as organ
transplant patients, those who are HIV posi-
tive, and those at early or late life stages, might
experience disproportionately higher disease
risk due to chemical exposure.
Periods of susceptibility. Exposure to envi-
ronmental chemicals during periods of suscep-
tibility can pose a unique risk of subsequent
downstream effects, both in the short and long
term, as well as diminished capacity for recov-
ery from decrements to physiological systems.
For example, exposure to thyroid-disrupting
chemicals such as perchlorate during the fetal
and early child development can produce
adverse effects on neurologic development by
decreasing TH levels; the same mild perturba-
tions in TH levels would not present an
adverse challenge to a healthy adult. Similarly,
to impair male reproductive development in
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Figure 2. Distribution of a typical physiological parameter within the population and how that may vary
depending on the influence of chemical and biologic background.
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rodents, exposure to phthalates must occur
during gestation days 12–19. When exposure
occurs during periods of developmental sus-
ceptibility, the dose required to produce an
effect will typically be lower than the dose
required to produce effects in fully developed,
healthy adults.
Multiple or complex modes of action.
Exposure to a chemical can influence disease
processes through multiple modes of action and
also increase the risk of more than one down-
stream, overt effect. Hence, measurements that
focus on a particular pathway or individual
downstream event may provide an incomplete
picture of the range of effects produced by the
chemical. Phthalates work through multiple
pathways to decrease androgen production but
also interfere with the production of INSL-3.
The resulting deficits in these hormones during
male fetal development can increase the risk of
several different downstream effects, both man-
ifested early in life (e.g., cryptorchidism) and
later in life (e.g., effects on sperm). Data inter-
pretations therefore should consider the possi-
bility of a complex set of modes of action that
produce adverse effects on the whole system.
Focusing on one single aspect of these complex
modes of action can result in inadequate
characterization of system response.
Continuous versus discrete events. Overt
downstream effects, such as cancer, birth
defects, and infectious illnesses are typically dis-
crete events. In contrast, upstream indicators of
adverse effects, such as changes in hormone
levels or cellular markers of immune function,
are often measured on a continuous scale. Risk
assessment practices recognize differences in
frequency of discrete events as an indication of
an adverse effect. Characterization of changes
in continuous outcomes in risk assessment
requires further consideration.
One key issue is assessing the level of
change constituting adversity. Should any
chemical-induced increase or decrease be con-
sidered adverse? Should there be a focus on
particular cut points in the distribution of
population or individual baseline levels? These
questions should be considered in the context
of the issues of background exposures and age-
related susceptibilities noted above. One possi-
bility is to consider that deviations from
expected baseline (e.g., for a given individual,
with all its characteristics, susceptibilities, age,
sex, physiologic state) will increase the proba-
bility (risk) of downstream adverse effects. For
example, changes in biological function dur-
ing susceptible periods, such as during devel-
opment, can increase risk of subsequent
downstream events compared to biological
function changes of the same magnitude at
other life stages. Whether the perturbation is
reversible and whether it is possible to use
population reference ranges to detect adversity
are two key questions that may arise in the
process of considering continuous upstream
indicators of adverse effects.
Reversibility. Biological perturbations
resulting from chemical exposure are often
evaluated in regard to whether they are
reversible. For example, exposure to chemicals
can result in immune system suppression and
increased opportunity for infections. A sup-
pressed immune system may recover once
chemical exposure is stopped, and the risk of
infectious disease returns to original levels.
However, for assessments of a constant chronic
or lifetime exposure, recovery from shorter
duration exposures should not be considered
when evaluating whether the observed response
is adverse. Whether a perturbation is reversible
can depend on intrinsic factors, such as age or
disease status, and extrinsic factors, such as pre-
existing or co-exposures to other contaminants
or the timing of exposure. For example, gesta-
tional and neonatal exposure to DZP and DES
in rodents can cause long-lasting effects on
immune function; in contrast, adult rodents
exposed to the same dose experience reversible
effects (Luebke et al. 2006).
Population variability and defining the
normal range. Basing the definition of “nor-
mal” function for a biologic parameter on
population reference ranges may not reflect
an individual’s normal range or variability
and may fail to detect an adverse effect. For
example, an individual may experience an
adverse decline in thyroid hormone but still
remain within the normal population refer-
ence range (Figure 1). For situations in which
the interindividual variability in a continuous
upstream indicator is high, alternative methods
to detect adverse changes in the biologic
parameter will need to be developed.
Conclusions and
Recommendations
Workshop participants concluded that for the
toxicity pathways represented in these case
studies, it may be feasible to move toward
using direct evaluation of upstream mechanis-
tic indicators as the basis for risk assessment
and decision-making.
The case studies illustrate the complexities
of the biological changes influenced by
exposures to environmental contaminants.
Capturing and translating the complexities of
the science is an ongoing challenge in the regu-
latory and policy arena. While science pursues
new areas of inquiry, decision making requires
timely answers to questions about risks and haz-
ards to public health in order to mitigate future
or current potential harm. The regulatory con-
text also requires a different sufficiency of evi-
dence whereby regulatory decisions can be
made based on evidence that a chemical is likely
to cause a particular outcome. The value of a
parallel-tracks approach was noted, in which
scientific investigation continues in one track
while development of appropriate principles
and practices for assessing the emerging science
for timely public health–based decision-making
continues in another.
Identifying classes of upstream events. The
case studies of thyroid perturbation, anti-
androgen activity, and certain types of immune
changes each represent a class of perturbations
whose links to downstream events were deter-
mined by workshop participants to be suffi-
ciently characterized by the data to move
toward considering issues of implementation.
A suggested next step is to evaluate chemicals
for their ability to cause the upstream pertur-
bation identified in the case studies. For these
chemicals, hazard and risk assessment could be
initiated with data on the relationship between
exposures and early perturbations. Fewer data
are needed for subsequent downstream events,
given what is already known on risks linking
the pathway from early to late events, and
with the presumption that downstream conse-
quences are likely to occur when the upstream
perturbation is observed.
Participants noted other types of early bio-
logical perturbations that were not discussed in
the case studies but that are also likely suffi-
ciently characterized as to be defined as a class.
Early biological perturbations that appeared to
be sufficiently characterized include certain
high affinity and persistent interactions with the
Ah receptor, changes in hormonal responses
[which are identified in reproductive toxicity
risk assessment guidelines as an adverse event
(U.S. EPA 1996)], and cholinesterase inhibi-
tion [which has been identified as an indicator
of adverse effects (U.S. EPA 2000b)]. It would
also be beneficial to expand the list to include
biological perturbations that appear common to
many environmental chemicals, such as effects
on birth weight or liver function.
Participants emphasized that additional
information on upstream indicators does not
necessarily reduce uncertainty, although it does
add more information about the exposure–
disease continuum and increases the predictive
power of risk assessment and can demonstrate
greater variability across study subjects than
previously recognized. Hence, using upstream
indicators does not necessarily mean reducing
applicable uncertainty or adjustment factors.
Next steps. The case studies suggest
chemical exposure–induced changes in
upstream biological markers have utility for
hazard identification and risk assessment. The
approaches to using these upstream indicators
should consider factors such as biological back-
ground, chemical background (and the poten-
tial for dose additivity or synergism), periods of
susceptibility, and multiple and complex
modes of action that can increase the risk of
subsequent downstream events. The case stud-
ies also illustrated the need to better integrate
the nonzero baseline concept into hazard and
Woodruff et al.
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risk assessment—in other words, background
exposures and processes can confer a greater
potential for effects than when exposure to a
chemical is considered in isolation. An impor-
tant implication of this concept is that the cur-
rent framework for addressing risks from
noncancer health effects no longer fits with
what we know about the science and needs of
the decision-maker for current understanding
of potential risk. Disease status, susceptibility,
and chemical background are critical to
consider when assessing the implications of
exposure, as they can put a portion of the
population in the dose range where small
incremental exposures can increase risk of
downstream events. This suggests that the
assumption of a threshold dose level—below
which no deleterious effects occur (U.S. EPA
2002)—may not apply, and incorporating
concepts traditionally used for nonthreshold
events should be considered.
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